Homepage

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Perez-Stable, Carlos, Ph.D.

Research Chemist, Miami VAHCS

Research Associate Professor of Medicine, University of Miami Miller School of Medicine

 

Contact Information

Location:           11 GRC, Miami VAHCS

Room CLC207

1201 NW 16 St

Miami, FL 33125

Office Phone: 305-324-4455 ext 4391

Lab Phone: 305-324-4455 ext 6253

Fax: 305-575-3365

Email: cperez@med.miami.edu

 

 

Affiliations

Geriatric Research, Education and Clinical Center (GRECC) and Research Service, Miami VAHCS

Division of Gerontology & Geriatric Medicine and Division of Endocrinology, Diabetes, and Metabolism, University of Miami Miller School of Medicine

 

 

Education
Undergraduate & Graduate

B.S. Microbiology, 1980; University of Florida, Gainesville, FL

Ph.D. Biochemistry, 1986; University of California, Davis, Davis, CA

 

Post-Graduate Training

Post-Doctoral Fellowship, 1986-1992; Department of Genetics and Development; Columbia University, NY, NY

 

 

Description of Research Expertise

Research Interests

1) Experimental therapeutics in prostate cancer

2) Mechanisms regulating cell death, cell cycle, and cell signaling of prostate cancer cells

3) Transgenic mouse models of prostate cancer

 

Key Words

Prostate cancer, apoptosis, necrosis, NF-kB, cyclin B1, anti-mitotic, cell signaling, transgenic mice, cancer stem cells, metastasis, mitochondria, nucleus

 

Research description

In Brief

Dr. Perez-Stable’s research program has focused on better understanding the mechanisms of how chemotherapeutic agents can stimulate cell death in prostate cancer cells. We have utilized the FG/Tag transgenic mouse model of aggressive metastatic prostate cancer and a variety of human prostate cancer cell lines to test the efficacy against androgen-independent prostate cancer (AI-PC) using 1) EB 1089 (a less calcemic and more potent analog of 1,25-dihydroxyvitamin D3); 2) 2-methoxyestradiol (2ME2; a metabolite of estradiol that blocks mitosis); 3) sequential combinations of docetaxel (antimitotic drug FDA approved for AI-PC) and flavopiridol (a pan-cyclin-dependent kinase inhibitor); and 4) low dose combinations of docetaxel and 2ME2. Currently, in a project funded by a VA Merit review, we are working on taking advantage of NF-B’s pro-death response to better kill a variety of prostate cancer cells, including the most aggressive and resistant to apoptotic cell death.

 

A separate but related project, previously funded by a VA Merit Review (2002-2005), is investigating the role of cyclin B1 in mediating cell death by chemotherapeutic agents. Our results have shown that prostate cancer cells that express higher levels of cyclin B1 protein are more sensitive to apoptosis induced by antimitotic drugs. We are currently investigating the downstream signals mediated by cyclin B1 and its partner CDK1 that are important for antimitotic drug induced cell death in prostate cancer cells.

 

 

Representative Publication

Gomez A, A de las Pozas, C Perez-Stable*. 2006. Sequential Combination of Flavopiridol and Docetaxel Reduces the Levels of XIAP and AKT Proteins and Stimulates Apoptosis in Human LNCaP Prostate Cancer Cells. Mol. Cancer Therapeutics 5: 1216-1226. *Corresponding author.

 

Reiner T, A de las Pozas, C Perez-Stable*. 2006. Sequential Combinations of Flavopiridol and Docetaxel Inhibit Prostate Tumors, Induce Apoptosis, and Decrease Angiogenesis, and in the G/T-15 Transgenic Mouse Model of Prostate Cancer. The Prostate 66:1487-1497. *Corresponding author.

 

Gomez LA, A de las Pozas, T Reiner, K Burnstein, C Perez-Stable*. 2007. Increased Expression of Cyclin B1 Sensitizes Prostate Cancer Cells to Apoptosis Induced by Chemotherapy. Mol. Cancer Therapeutics 6: 1534-1543*Corresponding author..

 

Reiner T, A de las Pozas, C Perez-Stable*. 2007. Progression of Prostate Cancer from a Subset of p63 Positive Basal Epithelial Cells in FG/Tag Transgenic Mice. Mol. Cancer Research 5: 1171-1179, 2007. *Corresponding author. Cover illustration and featured article.

 

Reiner T, A de las Pozas, LA Gomez, C Perez-Stable*. 2009. Low Dose Combination of 2-Methoxyestradiol and Docetaxel Can Block Prostate Cancer Cells in Mitosis and Induce Apoptosis. Cancer Letters 276: 21-31. *Corresponding author. Beyond the Abstract, UroToday.com, Feb. 5, 2009.


Yu, Hong, Ph. D.

Research Scientist, Miami VAHCS

Associate Professor, University of Miami Miller School of Medicine

 

Contact Information

Location:              Research Service VAM(151), Room211,

                1201 NW 16th street,

Miami FL 33125

Office Phone: 305-575-7000, ext 3998

Lab Phone: 305-575-7000, ext 6593, 4485

Fax: 305-575-3126

Email: hyu@med.miami.edu

 

Affiliations

Research Service, Miami VAHCS

Vascular Biology Institute, Department of cellular and Molecular Pharmacology, University of Miami School of Medicine

 

Education

Undergraduate and Graduate

B.S.
Fudan University, Shanghai, China, 1982.
Ph.D.
University of Southern California, 1993.

 

Post-Graduate Training
Post-doctoral Fellow – Gene Therapy Laboratory, University of Southern California School of Medicine with Dr. W. French Anderson, 1993-1996.

Description of Research Expertise

Research Interests

-Impact of aging on CXCR4 surface expression on bone marrow-derived cells

-CXCR4/SDF-1 interaction and signaling pathway
-Mobilization and homing of Progenitor cells
-Roles of progenitor cells in angiogenesis and atherosclerosis.

 

Key Words

CXCR4, SDF-1, bone marrow cells, endothelial progenitor cells, angiogenesis, atherosclerosis, cardiovascular diseases, mobilization, migration, engraftment.

 

Research description

Vascular occlusion resulting in ischemia is a major cause of heart attack, stroke and peripheral arterial disease.  Angiogenesis (natural revascularization) is stimulated by the signaling factors released from the ischemia tissue. Bone marrow-derived cells (BMC) are mobilized into circulation in response to signaling proteins. Among these proteins, the chemotactic cytokine Stromal Cell Derived Factor-1 (SDF-1) is particularly important as an initiator of angiogenesis and vascular repair. SDF-1 acts through binding with the cell surface receptor known as CXCR4. As a result of SDF-1/CXCR4 axis signaling, the BMCs home to the ischemic tissue where they participate in new vessel growth. The amount of surface CXCR4 expression on progenitor cells is critical for the ability of cells being mobilized and engrafted.

 

The focus of our laboratory is to identify the specific changes in CXCR4 surface expression and SDF-1/CXCR4 signaling pathway which is responsible for the impaired revascularization ability of aged BMCs.  We have found that aging adversely impacts angiogenesis. SDF-1 is inefficient to promote angiogenesis in aged mice. CXCR4 surface expression on BMC from old mice is significantly lower than that of young mice.  We are studying the impact of aging on CXCR4 expression in the subpopulations of BMC, and the causes for the reduced CXCR4 surface expression on BMC from old mice.  We try to determine the aging effect on SDF-1/CXCR4 signaling, including Akt phosphorylation, eNOS activation and ROS production. We are illustrating in vitro the effect of differential surface CXCR4 expression on progenitor cell migration, tube formation, and its interaction with mature endothelial cells. We are studying how precursor cells homing to ischemic tissues and what functions they provide during neovascularization using a hindlimb ischemia mouse model.

 

Another project is to study the role of Bone marrow-derived cells, particularly neutrophil granulocytes, in atherosclerosis. We are studying the role of CXCR4 expression on the homing of neutrophil onto plaques, and will determine the contribution of neutrophils to plaque formation in an atherosclerotic prone ApoE knockout mouse model. These fundamental mechanistic studies will enhance our understanding of stem cell biology, and will enable us to refine cell-based therapeutic strategies for vascular diseases.

 

 

Representative Publication

1.          Tan, Y, Shao H, Eton D, et al, Yu H. Stromal Cell-Derived Factor-1 Enhances Pro-Angiogenic Effect of Granulocyte Colony Stimulating Factor. Cardiovasc Res. 73: 823-832, 2007.

http://www.ncbi.nlm.nih.gov/pubmed/17258698

 

2.          Shao H, Tan Y, et al., Yu H. Statin and Stromal Cell Derived Factor-1 Additively Promote Angiogenesis by Enhancement of Progenitor Cells Incorporation into New Vessels. Stem Cells. 26:1376-1384, 2008.

          http://www.ncbi.nlm.nih.gov/pubmed/18308946

 

3.          Yu H, Feng Y. The Potential of Statin and Stromal Cell-derived Factor-1 to Promote Angiogenesis. Cell Adhesion and Migration. 2 (4):254-257, 2008.

          http://www.landesbioscience.com/journals/celladhesion/article/6818

 

4.          Wu Q, Shao H, Eton D, et al., Webster KA, Yu H Extracellular calcium increases CXCR4 Expression on Bone Marrow-derived Cells and Enhances Pro-Angiogenesis Therapy.  J Cell Mol Med. 2009 In press. DOI 10.1111/j.1582-4934.2009.00691.x

          http://www.ncbi.nlm.nih.gov/pubmed/19220581

 

5.          Tan Y, Li Y, et al., Webster KA, Yan J, Yu H, Cai L and Li X. A novel CXCR4 antagonist derived from human SDF-1b enhances angiogenesis in ischemic mice. Cardiovascular Res. 82:513-521, 2009.

          http://www.ncbi.nlm.nih.gov/pubmed/19196827